The FDA has approved an IND for a Phase 2 study of GeneOne Life Science's GLS-1200 nasal spray for the prevention of COVID-19, the company said. According to GeneOne, GLS-1200 stimulates nasal production of nitric oxide, which has been shown to inhibit coronavirus activity. The study of GLS-1200 for prevention of COVID-19 is expected to enroll 225 healthcare … [Read more...] about FDA approves IND for Phase 2 study of GeneOne Life Science nasal spray for the prevention of COVID-19
Medical
AAAAI publishes new data showing bioequivalence of ARS Pharmaceuticals’ ARS-1 epinephrine nasal spray to injected epinephrine
The American Academy of Allergy, Asthma & Immunology (AAAAI) has published results of three Phase 1 studies of ARS Pharmaceuticals' ARS-1 (Neffy) intranasal epinephrine that had been scheduled for presentation at the AAAAI annual meeting. The FDA granted Fast Track designation to the ARS-1 for the treatment of anaphylaxis in February 2019. The studies, EPI … [Read more...] about AAAAI publishes new data showing bioequivalence of ARS Pharmaceuticals’ ARS-1 epinephrine nasal spray to injected epinephrine
Alnylam and Vir select candidate for development as inhaled COVID-19 vaccine
Alnylam Pharmaceuticals and Vir Biotechnology have announced that they intend to meet with the FDA soon regarding an IND for VIR-2703 (ALN-COV), an inhaled siRNA in development for prevention and/or treatment of COVID-19. The companies said that VIR-2703 may also have activity against other coronaviruses. The collaboration agreement between Vir and Alnylam includes … [Read more...] about Alnylam and Vir select candidate for development as inhaled COVID-19 vaccine
Fluidda study suggests that inhaled vasodilators may be helpful in COVID-19
Functional respiratory imaging (FRI) company Fluidda has announced that an FRI study of COVID-19 patients has shown that the virus is resulting in narrowing of small capillaries in the lung, resulting in higher flow pressures that in turn causes higher pressure in the main blood vessels and suggests that vasodilators delivered to the lung may be a useful therapy. … [Read more...] about Fluidda study suggests that inhaled vasodilators may be helpful in COVID-19
Marinomed gets funding for development of Carragelose inhalation solution for the treatment of COVID-19 pneumonia
Marinomed Biotech has announced new funding from the Austrian Research Promotion Agency (FFG) for development of a Carragelose inhalation solution for COVID-19 pneumonia. The funding is part of the FFG's "Emergency Call to research COVID-19 in the wake of the outbreak of SARS-CoV-2." Carragelose is a polymer derived from red seaweed that has shown activity against … [Read more...] about Marinomed gets funding for development of Carragelose inhalation solution for the treatment of COVID-19 pneumonia
Alpha Cognition and Linical partner on potential intranasal therapy for Alzheimer’s disease
Alpha Cognition Inc. (formerly Neurodyn Cognition) and CRO Linical have announced Linical will provide consulting services related to potential development of Alpha Cognition's Alpha-1062 acetyl choline esterase inhibitor (AChEI) for the treatment of Alzheimer's disease. Linical's services are expected to encompass a range of areas, including regulatory guidance, … [Read more...] about Alpha Cognition and Linical partner on potential intranasal therapy for Alzheimer’s disease
Phase 2a trial of Biomarck’s inhaled peptide for acute respiratory distress syndrome meets its primary endpoint
Biomarck Pharmaceuticals said that a Phase 2a clinical trial of its BIO-11006 inhalation solution in patients with acute respiratory distress syndrome (ARDS) met its primary endpoint, with a 43% decrease in mortality at 28 days compared to placebo. According to Biomarck, previous studies have shown that BIO-11006, the 10 amino acid N-terminal of a protein called … [Read more...] about Phase 2a trial of Biomarck’s inhaled peptide for acute respiratory distress syndrome meets its primary endpoint
Theravance Biopharma initiates Phase 1 study of TD-0903 inhaled JAK inhibitor
Theravance Biopharma said that a Phase 1 study of its TD-0903 nebulized JAK inhibitor is now underway. Earlier this month, Theravance announced that it intended to begin clinical development of TD-0903 for the prevention of cytokine storm, which can lead to acute respiratory distress syndrome, in patients hospitalized due to COVID-19. The Phase 1 SAD/MAD study … [Read more...] about Theravance Biopharma initiates Phase 1 study of TD-0903 inhaled JAK inhibitor
University of Waterloo researchers working on intranasal vaccine against COVID-19
The University of Waterloo has announced that School of Pharmacy faculty members Roderick Slavcev and Emmanuel Ho are collaborating with Chemical Engineering professor Marc Aucoin on development of an intranasal vaccine against COVID-19. According to the announcement, Slavcev is modifying his group's existing bacteriophage vaccine technology for the COVID-19 vaccine … [Read more...] about University of Waterloo researchers working on intranasal vaccine against COVID-19
Enterin announces planned study of inhaled therapy for COVID-19
US-based Enterin Inc. announced that it has been in talks with the FDA in preparation for a Phase 1/2a study of a nebulized formulation of its COV-ENT-1 in patients hospitalized with COVID-19. The company said that it plans to develop a dry powder COV-ENT-1 for inhalation if the study is successful. Enterin's lead candidate, ENT-01 (kenterin), is currently in Phase 2 … [Read more...] about Enterin announces planned study of inhaled therapy for COVID-19